Dermoscopic features in a case of dyschromatosis symmetrica hereditaria

Oiso, Naoki; Murata, Ichidai; Hayashi, Masahiro; Amatsu, Akinori; Yoshida, Manami; Suzuki, Tamio; Kawada, Akira

doi:10.1111/j.1346-8138.2010.01110.x

Cited by 12 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dermoscopic examination showed six patterns: reticulate hyperpigmented spots, diffuse pigmentation with hyperpigmented dots, reticulate pigmented spots, monotonous pigmented spots, reticulate hypopigmented spots and monotonous hypopigmented spots (Fig 1d). 2 All the clinical features and dermoscopic findings supported the diagnosis of DSH.…”

mentioning

confidence: 66%

A novel frameshift mutation of the ADAR1 gene in a Chinese patient with dyschromatosis symmetrica hereditaria and the dermoscopic features

Chi

Luo

Liu

2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

mentioning

confidence: 66%

A novel frameshift mutation of the ADAR1 gene in a Chinese patient with dyschromatosis symmetrica hereditaria and the dermoscopic features

Chi

Luo

Liu

2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

“…Dermoscopy of the pigmented areas can show reticulated hyperpigmented spots, reticulate pigmented spots, monotonous pigmented spots, reticulated hypopigmented spots, or monotonous hypopigmented spots [ 18 ].…”

Section: Dyschromatosis Symmetrica Hereditariamentioning

confidence: 99%

Clinical and Genetic Review of Hereditary Acral Reticulate Pigmentary Disorders

Alshaikh

Alsaif

Aldukhi

2017

Dermatology Research and Practice

View full text Add to dashboard Cite

Reticulated pigmentation is a unique pigmentary change caused by a heterogeneous group of hereditary and acquired disorders. This pigmentation is characterized by a mottled appearance, with lesions that vary in size and pigmentary content. This review discusses the hereditary group of the reticulated pigmentation disorders, such as dyschromatosis symmetrica hereditaria, dyschromatosis universalis hereditaria, and reticulate acropigmentation of Kitamura. The clinical presentation and histopathological features often overlap, making diagnosis difficult. However, each of these hereditary conditions possesses a unique genetic mutation, and genetic analysis is thus more useful in the diagnosis of these conditions. This article delivers an update regarding the clinical features, detailed histopathological description, and genetic information concerning hereditary reticulate pigmentary disorders and aims to provide useful background for use by clinical dermatologists and histopathologists when approaching this group of hereditary disorders.

show abstract

“…Vitrase®, Bausch&Lomb, Rochester, NY, USA). The addition of hyaluronidase to local anesthetics has been shown to enhance safely and effectively the diffusion of the drug, thereby increasing the analgesic efficacy especially in the first minutes after injection [12,13]. …”

Section: Introductionmentioning

confidence: 99%

Hyaluronidase injection for the treatment of eyelid edema: a retrospective analysis of 20 patients

et al. 2014

View full text Add to dashboard Cite

BackgroundHyaluronidase (Hylase Dessau®) is a hyaluronic acid-metabolizing enzyme, which has been shown to loosen the extracellular matrix, thereby improving the diffusion of local anesthetics. Lower eyelid edema is a common post-interventional complication of cosmetic procedures performed in the lid region, such as the injection of hyaluronic acid fillers for tear-trough augmentation. The purpose of this study was to validate the efficacy of hyaluronidase in the management of lower eyelid edema.MethodsWe performed a retrospective analysis with 20 patients with lower eyelid edema. Most patients (n = 14) presented with edema following hyaluronic acid injection (tear-trough augmentation), whereas the minority (n = 6) were treated due to idiopathic edema (malar edema or malar mounds). Patients were treated by local infiltration of approximately 0.2 ml to 0.5 ml of hyaluronidase (Hylase Dessau® 20 IU to 75 IU) per eyelid. Photographs were taken prior to and seven days after infiltration.ResultsHyaluronidase was found to reduce effectively and rapidly or resolve eyelid edema after a single injection. No relevant adverse effects were observed. However, it must be noted that a hyaluronidase injection may also dissolve injected hyaluronic acid fillers and may therefore negatively affect tear-trough augmentations. While the effects of a treatment for edema due to tear-trough augmentation were permanent, malar edema and malar mounds reoccurred within two to three weeks.ConclusionThe infiltration of hyaluronidase is rapid, safe and currently the only effective option for the management of eyelid edema. No relevant adverse effects were observed.

show abstract

Dermoscopic features in a case of dyschromatosis symmetrica hereditaria

Cited by 12 publications

References 12 publications

A novel frameshift mutation of the ADAR1 gene in a Chinese patient with dyschromatosis symmetrica hereditaria and the dermoscopic features

A novel frameshift mutation of the ADAR1 gene in a Chinese patient with dyschromatosis symmetrica hereditaria and the dermoscopic features

Clinical and Genetic Review of Hereditary Acral Reticulate Pigmentary Disorders

Hyaluronidase injection for the treatment of eyelid edema: a retrospective analysis of 20 patients

Contact Info

Product

Resources

About